Geode Capital Management LLC Raises Stock Holdings in Greenwich LifeSciences, Inc. (NASDAQ:GLSI)

Geode Capital Management LLC boosted its holdings in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) by 4.6% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 133,550 shares of the company’s stock after acquiring an additional 5,861 shares during the quarter. Geode Capital Management LLC owned 1.02% of Greenwich LifeSciences worth $1,919,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Barclays PLC raised its position in Greenwich LifeSciences by 323.3% during the 3rd quarter. Barclays PLC now owns 8,560 shares of the company’s stock valued at $123,000 after purchasing an additional 6,538 shares in the last quarter. State Street Corp increased its stake in shares of Greenwich LifeSciences by 4.4% during the third quarter. State Street Corp now owns 71,408 shares of the company’s stock valued at $1,026,000 after buying an additional 3,005 shares during the period. Garden State Investment Advisory Services LLC bought a new stake in shares of Greenwich LifeSciences in the third quarter valued at about $253,000. Rhumbline Advisers purchased a new stake in Greenwich LifeSciences in the second quarter worth about $117,000. Finally, Bank of New York Mellon Corp bought a new position in Greenwich LifeSciences during the 2nd quarter worth about $264,000. Institutional investors own 4.16% of the company’s stock.

Greenwich LifeSciences Stock Performance

NASDAQ GLSI opened at $13.35 on Thursday. Greenwich LifeSciences, Inc. has a one year low of $8.00 and a one year high of $21.44. The company has a market capitalization of $175.49 million, a price-to-earnings ratio of -16.69 and a beta of 1.66. The company’s 50-day simple moving average is $13.15 and its two-hundred day simple moving average is $14.13.

Insider Activity

In related news, CEO Snehal Patel acquired 3,200 shares of the firm’s stock in a transaction that occurred on Monday, December 30th. The stock was purchased at an average cost of $11.12 per share, for a total transaction of $35,584.00. Following the purchase, the chief executive officer now directly owns 5,539,302 shares of the company’s stock, valued at $61,597,038.24. This trade represents a 0.06 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this link. Over the last ninety days, insiders have acquired 8,000 shares of company stock worth $97,184. Corporate insiders own 51.67% of the company’s stock.

Greenwich LifeSciences Profile

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.